22.73M
Market cap
Current P/E
Forward P/E

About

Health care
Sector
Biotechnology
Industry

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain.

Similar securities

Based on sector and market capitalization

Report issue